SCHEMBL6444863

SCHEMBL6444863

N#Cc1c(OCc2ccncc2)nc(N)nc1-c1ccco1

nearest known ligand 0.54

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 15/20 0.54
ADORA1 P30542 14/20 0.54
ADORA2B P29275 6/20 0.54
ADORA3 P0DMS8 5/20 0.47
MGMT P16455 2/20 0.46
KDM4E B2RXH2 2/20 0.40
MEN1 O00255 2/20 0.40
ALDH1A1 P00352 2/20 0.40
GAA P10253 2/20 0.40
MAPT P10636 2/20 0.40
HPGD P15428 2/20 0.40
TSHR P16473 2/20 0.40
KMT2A Q03164 2/20 0.40
ALOX15 P16050 1/20 0.40
MAPK1 P28482 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
HSD17B10 Q99714 1/20 0.40
GLA P06280 1/20 0.39
POLB P06746 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5046632 0.91 ADORA2A (0.62) ADORA2AADORA1ADORA2BADORA3MGMT
SCHEMBL5133729 0.88 ADORA1 (0.51) ADORA2AADORA1ADORA2BADORA3MGMT
SCHEMBL5132654 0.84 ADORA2A (0.54) ADORA2AADORA1ADORA2BADORA3KDM4E
SCHEMBL5041663 0.83 ADORA2A (0.56) ADORA2AADORA1ADORA2BADORA3MGMT
SCHEMBL5039900 0.83 ADORA2A (0.50) ADORA2AADORA1ADORA2BADORA3KDM4E
SCHEMBL5046844 0.82 ADORA1 (0.60) ADORA2AADORA1ADORA2BKDM4EMEN1
SCHEMBL5131947 0.81 ADORA1 (0.50) ADORA2AADORA1ADORA2BADORA3KDM4E
SCHEMBL5044494 0.81 ADORA2A (0.50) ADORA2AADORA1ADORA2BADORA3KDM4E
SCHEMBL5037058 0.80 ADORA2A (0.60) ADORA2AADORA1ADORA2BADORA3KDM4E
SCHEMBL5044502 0.80 ADORA2A (0.54) ADORA2AADORA1ADORA2BADORA3KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1261327-B1 ADENOSINE RECEPTOR MODULATORS HOFFMANN LA ROCHE (CH) 2005-04-27 EP disclosed
US-6586441-B2 2-Amino-6-benzylsulfanyl-4-thiophen-2-yl-pyridine-3,5-dicarbo -nitrile as an examplary preferred compound; Alzheimer's and Parkinson's diseases; neuroprotectors; schizophrenia, analgesics; anxiolytic agents; respiratory disorders HOFFMAN-LA ROCHE INC. 2003-07-01 US disclosed
EP-1261327-A2 ADENOSINE RECEPTOR MODULATORS F.HOFFMANN-LA ROCHE AG (CH) 2002-12-04 EP disclosed
US-20010027196-A1 Adenosine receptor ligands and their use in the treatment of disease F. HOFFMANN-LA ROCHE AG (CH) 2001-10-04 US disclosed
WO-2001062233-A2 ADENOSINE RECEPTOR MODULATORS F. HOFFMANN LA ROCHE AG (CH) 2001-08-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010027196-A1 Adenosine receptor ligands and their use in the treatment of disease ADORA2A, ADORA2B, ADORA1 ADORA2A 1/4885ADORA1 3/4885ADORA2B 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.